ment
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.
MENT is used for rapid lean-mass and strength gain, aggressive recomposition, and unusually strong on-cycle libido.
MENT aromatizes to 7alpha-methylestradiol, a potent estrogen that standard aromatase inhibitors may not control well at community doses. Gynecomastia, water retention, and blood pressure movement can show up within the first 1-2 weeks, so this is not a compound to start without baseline labs, home blood pressure tracking, and SERM access already in place.
MENT is used for rapid lean-mass and strength gain, aggressive recomposition, and unusually strong on-cycle libido. Its appeal is high anabolic output without DHT amplification in scalp and prostate tissue, but that advantage comes with severe suppression, daily injections, and a difficult estrogen profile rather than an easier testosterone replacement baseline.
Severe and rapid HPG suppression (90% LH/FSH drop within 4 weeks, roughly 12x more suppressive than testosterone mg-for-mg); aggressive aromatization to 7alpha-methylestradiol causing gynecomastia and hypertension if AI management is insufficient; HDL suppression (~14% in clinical studies); blood pressure elevation; fertility suppression persisting 6-12 months post-cycle.
MENT offers one of the strongest anabolic effects per milligram in the injectable AAS category, with preclinical work summarized here at roughly 10x testosterone's myotropic potency. The value case is strongest for advanced users seeking tren-like recomposition while avoiding trenbolone's sleep and mood burden; it falls apart when the user cannot manage estrogen, recovery, fertility risk, and product-identity confidence.
Community consensus is bullish but bounded: experienced users who control estrogen often rate MENT highly for strength, recomposition, and libido, while poor experiences cluster around fast gynecomastia, water retention, blood pressure elevation, and slow recovery. The efficacy signal is strong, but the practical bar is specialist-level.
Do not stack trestolone with nandrolone (Deca, NPP) or trenbolone — additive 19-nor suppression, compounded estrogen and prolactin management burden, and no additive benefit over running trestolone alone or with testosterone.
Intro
Trestolone acetate (MENT, 7alpha-methyl-19-nortestosterone) is a synthetic androgen developed by the Population Council primarily as a male hormonal contraceptive.
It was never approved for clinical use. Structurally, MENT is derived from nandrolone with a 7alpha-methyl group added to the steroid nucleus. This substitution prevents 5alpha-reduction by 5alpha-reductase, so MENT does not convert to a DHT-equivalent in androgenic target tissues such as the prostate and scalp. However, it does not block aromatization; MENT is converted by CYP19A1 to 7alpha-methylestradiol (7alpha-MeE2), a potent estrogen. Critically, 7alpha-MeE2 is less efficiently inhibited by standard aromatase inhibitors (anastrozole, exemestane, letrozole), which were developed to suppress estradiol-17beta. MENT does not bind sex hormone-binding globulin (SHBG), meaning essentially all circulating MENT is free and biologically active. In preclinical bioassay, MENT demonstrates approximately 10x the myotropic potency of testosterone and approximately 12x the suppressive potency on gonadotropin secretion. The Walton 2007 study (n=29, 48 weeks of MENT acetate implants at contraceptive doses) documented 90% suppression of LH and FSH within 4 weeks, HDL reduction of approximately 14%, triglyceride increase of approximately 13%, and transient systolic blood pressure elevation that normalized post-therapy. Hematocrit did not significantly change. Community use centers on injectable acetate preparations; the acetate ester confers an effective half-life of roughly 24 hours, necessitating daily injection at typical community doses of 25-75 mg per day.
Observed Effects
Community users and preclinical data converge on rapid lean mass accrual within 2-3 weeks of initiation — faster onset than most injectable androgens at equivalent anabolic dose-equivalents.
Strength gains are described as dramatic across compound movements. Body composition changes include simultaneous fat loss and lean mass gain at maintenance calories, consistent with a tren-like recomposition effect attributed to high androgen receptor binding affinity and myotropic potency. Libido is consistently described as elevated and frequently cited as superior to nandrolone cycles. Skin fullness and vascularity increase notably. Users managing estrogen aggressively report lean, hard, vascular physiques. Neurological effects are mild relative to trenbolone — users describe better sleep, less anxiety, and fewer mood disturbances. Cognitive sharpness is not negatively impacted in most community reports.
Field Reports
Experienced users describe MENT cycles as delivering recomposition results comparable to trenbolone without sleep disruption, aggression, and cardiovascular stress.
Strength gains within 2-3 weeks are a consistent report. Libido is described as strong to very strong and frequently noted as superior to nandrolone cycles. Users with prior trenbolone experience frequently describe MENT as superior on a quality-of-life basis. Negative experiences center on estrogenic issues: users report gynecomastia developing within 10-14 days despite running anastrozole, consistent with reduced AI efficacy against 7alpha-MeE2. Blood pressure management requires active monitoring, particularly when estrogen is not controlled. Post-cycle recovery is described as slower than testosterone cycles; reports of low libido and fatigue persisting 8-12 weeks post-cycle even with standard PCT are consistent with clinical fertility recovery data.
Community Consensus
MENT has been discussed in advanced AAS communities since roughly 2010-2012, when injectable acetate preparations began appearing through research-chemical channels.
The consensus is not that MENT is weak or speculative; the consensus is that it is potent, fast, and unforgiving. Favorable reports usually come from users who already understand estrogen management, recovery labs, blood pressure tracking, and short-ester injection logistics. Negative reports cluster around the same failure pattern: assuming a testosterone-cycle AI plan will control 7alpha-methylestradiol, then developing water retention, nipple symptoms, blood pressure elevation, or a messy recovery. Availability remains a second limiting factor because raw material is expensive, supply is intermittent, and underdosing or substitution can turn the whole protocol into guesswork.
Risks & Monitoring
The dominant adverse effect profile is driven by aromatization to 7alpha-methylestradiol. Water retention and gynecomastia can develop rapidly — within 1-2 weeks — because standard AI efficacy against 7alpha-MeE2 is reduced.
Systolic blood pressure elevation correlates with estrogen-driven fluid retention. HDL suppression (~14% in Walton 2007) reflects androgenic cardiovascular impact. Hematocrit does not appear to rise significantly, contrasting favorably with testosterone at equivalent anabolic doses. HPG axis suppression is severe and rapid — LH and FSH reach near-zero within 4 weeks. Testicular atrophy during cycle is expected and pronounced. Post-cycle fertility recovery takes 6-12 months in clinical data. Acne incidence is moderate — lower than testosterone-based cycles, consistent with the absence of DHT conversion. Prostate stimulation is reduced versus testosterone. Androgenic alopecia is similarly reduced. Night sweats and mood disturbances are less common than with trenbolone but can occur at high doses. Prolactin elevation is not expected, distinguishing MENT from nandrolone-class compounds.
For Women
Monitoring Panels
REQUIRED is a real safety gate. RECOMMENDED is the prudent default. OPTIONAL covers symptoms, risk factors, or tighter tracking.
Confirm pre-cycle gonadotropin baseline. Suppression to near-zero expected within 4 weeks.
Establish testosterone baseline for post-cycle recovery reference. E2 sensitive as proxy for estrogen burden; 7alpha-MeE2 may not be captured but correlate to symptoms.
HDL suppression ~14% documented in clinical studies. Baseline required to track magnitude. Reassess midcycle.
Hematocrit did not significantly elevate in Walton 2007, but community doses are higher, often stacked, and still require a CBC baseline.
Liver function baseline; injectable MENT has low direct hepatotoxicity but hepatic monitoring is standard and especially important if oral ancillaries are co-administered.
Systolic BP elevation documented in clinical studies. Daily home monitoring; target below 130/80 during cycle.
Reassess HDL suppression, confirm gonadotropin suppression, and compare estrogen burden against symptoms. Estradiol sensitive is an imperfect proxy because 7alpha-MeE2 may not be captured, but it still helps separate standard E2 movement from symptom-only guessing.
MENT was developed as a male contraceptive and the article flags 6-12 month fertility recovery. Semen analysis belongs in the plan when conception within the next year would change the decision.
Assess HPG axis recovery. Recommended at 6 weeks post-PCT; secondary at 12 weeks if recovery is incomplete. Fertility recovery can take 6-12 months.
Avoid With
Do not combine ment with the following. Sorted highest-severity first.
Why:Both MENT and nandrolone are 19-nor compounds. Stacking produces additive HPG suppression with no additive anabolic benefit over MENT alone. Nandrolone also elevates prolactin, adding a separate management burden.
What to do:Community consensus: do not stack 19-nors. MENT plus nandrolone is redundant and high-suppression.
Why:Trenbolone is a 19-nor derivative. Stacking with MENT produces compounded suppression and additive androgenic side effects with no clear synergy. MENT's advantage over trenbolone is reduced neuropsychiatric burden; stacking eliminates that advantage.
What to do:Users who run both report worst-of-both side effect profiles with no proportional benefit.
Why:Adding high-dose testosterone to MENT creates two simultaneous estrogen burdens (E2 from testosterone aromatization; 7alpha-MeE2 from MENT aromatization), each requiring management but with different AI sensitivity profiles.
What to do:Low-dose testosterone base (100-200 mg/week) is compatible. High-dose stacking is not recommended.
Why:Adding 17alpha-alkylated oral steroids creates compound hepatic stress. MENT acetate alone has low hepatotoxicity but oral AAS additions change the risk calculus.
What to do:If orals are used alongside MENT, add TUDCA and run liver function panel midcycle.
Protocols By Goal
Recomposition reports usually describe MENT acetate in the 25-50 mg/day range for 8-10 weeks with aggressive estrogen monitoring and support planned in advance.
Some users report adding low-dose testosterone; others report MENT-only cycles. Bulk and strength reports move higher, often 50-75 mg/day, but the estrogen, blood-pressure, lipid, and suppression burden rises quickly. Cutting reports are advanced edge cases, not a beginner lane.
Post-cycle recovery reports commonly use SERM-based PCT shortly after the last acetate injection because the ester is short. This is not a medical protocol; the practical point is that MENT recovery is unusually suppressive and fertility recovery can take months.
Dosing Details
Reported community injectable-acetate patterns most often describe 25-50 mg/day for experienced users, 50-75 mg/day as an advanced high-side range, and sub-25 mg/day as a conservative first-exposure pattern.
Cycle reports commonly cluster around 8-12 weeks, with shorter 6-week blocks used to limit suppression duration. Clinical contraceptive exposure in Walton 2007 was far lower, roughly 2-4 mg/day via subcutaneous implant, which should not be conflated with hypertrophy-oriented community use. This section describes observed practice, not a recommendation.
Stacks & Alternatives
Low-dose testosterone (100-200 mg/week) is commonly added to maintain baseline androgen signaling. MENT suppresses endogenous testosterone; exogenous testosterone prevents complete androgen withdrawal syndrome.
Standard AI for estrogen management, though reduced efficacy against 7alpha-methylestradiol means higher doses or more frequent dosing than on testosterone cycles. Exemestane (steroidal) may have marginal advantage over anastrozole (non-steroidal) against 7alpha-MeE2.
SERM for gynecomastia prevention and PCT. Because AI efficacy is reduced against 7alpha-MeE2, many users keep a SERM on hand during cycle. Raloxifene is preferred for active gynecomastia treatment; tamoxifen is the standard PCT SERM.
Standard PCT addition alongside tamoxifen. Nolvadex 40/40/20/20 + Clomid 50/50/25/25 is the community-consensus PCT protocol for MENT cycles.
Hepatoprotection if oral ancillaries are co-administered. Not required for MENT acetate itself but prudent if orals are part of the protocol.
Alternatives
Stack Cost
Specialist tax: MENT is a high-potency 19-nor injectable that trades low DHT conversion for severe suppression, difficult estrogen control, daily injection logistics, fertility shutdown, and fragile sourcing.
The article states MENT suppresses LH and FSH with roughly 12x the per-mg potency of testosterone, with Walton 2007 documenting about 90% LH/FSH suppression within 4 weeks and 6-12 month fertility recovery.
The article flags HDL suppression around 14%, triglyceride increases around 13%, and transient systolic blood pressure elevation, with community blood pressure risk amplified by estrogen-driven fluid retention.
stackingConflicts hard-excludes nandrolone and trenbolone, cautions against high-dose testosterone, and warns that oral methylated additions change the hepatic risk surface.
The article treats daily injection as non-negotiable because the acetate ester has an effective half-life of roughly 24 hours and skipped days produce noticeable energy and mood fluctuations.
womenConsiderations marks virilization risk high and recommends against use in women, while practicalConsiderations says MENT is contraindicated if conception is planned within 12 months.
- ·Counts as the 19-nor lane; do not stack with nandrolone, NPP, or trenbolone.
- ·Counts as a full suppression and fertility-capacity consumer; avoid when near-term fertility or uncertain post-cycle recovery is unacceptable.
- ·Counts as an estrogen-management problem from 7alpha-methylestradiol; AI access alone is not enough, and a SERM should be available before the cycle starts.
- ·Counts as a cardiovascular and lipid-capacity consumer; do not add when baseline HDL, blood pressure, or cardiovascular risk is already poor.
- ·Counts as a daily-injection logistics commitment; inconsistent dosing undermines the risk plan.
- ·Daily acetate injections with site rotation.
- ·Aggressive estrogen plan from week 1, typically AI plus SERM access for gynecomastia risk.
- ·Baseline and follow-up LH, FSH, total/free testosterone, estradiol sensitive, lipid panel, CBC, CMP, and blood pressure monitoring.
- ·PCT beginning about 3 days after the last acetate injection in the article's protocol framing.
- ·Fertility patience and repeat recovery labs because clinical recovery can take 6-12 months.
The quickSummary labels MENT advanced, and the article requires daily injection, estrogen management that may not respond normally to standard AIs, suppression recovery planning, fertility caution, and source testing.
- ·No experience managing estrogen symptoms and labs
- ·No home blood pressure monitoring
- ·Near-term fertility goal or unwillingness to accept 6-12 month recovery uncertainty
- ·Plan to stack multiple 19-nors
- ·Unverified research-chemical source
The acetate ester clears quickly enough for fast protocol changes, but the article frames suppression and fertility recovery as prolonged, with PCT starting 3 days after the last injection and recovery labs needed at 6 and 12 weeks or longer.
- ·Near-zero LH and FSH requiring recovery monitoring
- ·Fertility recovery may take 6-12 months
- ·Estrogen symptoms can outlast simple AI assumptions because 7alpha-methylestradiol is difficult to manage
- ·Libido, mood, and energy may drop during transition if recovery or base androgen support is mishandled
- ·HDL, triglycerides, and blood pressure may need time to normalize
Do not start without AI and SERM access. Treat symptom-only estrogen management as inadequate and reduce or stop if gynecomastia or blood pressure moves quickly.
Avoid MENT when conception is planned within 12 months. Monitor LH, FSH, testosterone, and fertility-specific endpoints when fertility matters.
Follow the article's redline: run MENT alone or with low-dose testosterone support rather than stacking 19-nors.
Use analytical testing where possible and avoid adjusting ancillaries around an unverified identity or concentration.
The article explicitly contraindicates MENT when fertility is needed in that window because clinical recovery can take 6-12 months.
womenConsiderations classifies virilization risk as high and recommends against use in women.
The article documents HDL suppression and blood pressure elevation, with estrogen-driven fluid retention as the dominant acute management problem.
MENT aromatizes to 7alpha-methylestradiol, and the article warns standard AI management may be inadequate at community doses.
Practical Setup
Daily-use reports reflect the short acetate half-life: missed days can produce noticeable energy and mood fluctuations. Injection-site rotation and sterile technique are clinician-context topics, not public how-to.
The main practical issue is estrogen control. Experienced reports emphasize having a monitoring and response plan before exposure rather than reacting after water retention, nipple symptoms, or blood-pressure elevation appears. Biomarker tracking usually centers on blood pressure, sensitive estradiol, HDL/lipids, liver enzymes if oral ancillaries are used, LH/FSH recovery, and testosterone after recovery attempts.
Fertility intent is a hard context limit: if conception is planned within 12 months, MENT is a poor fit. Product identity and underdosing/substitution risk add uncertainty, but public prose should not turn that into sourcing instructions.
Mechanism Deep Dive
MENT (7alpha-methyl-19-nortestosterone) binds the androgen receptor with high affinity — preclinical data shows approximately 10x the myotropic potency of testosterone in levator ani assays.
The 7alpha-methyl group provides steric hindrance preventing 5alpha-reductase from catalyzing reduction to a more potent 5alpha-reduced metabolite; consequently, MENT does not amplify androgenic signal in tissues where 5alpha-reductase activity is high (prostate, scalp, skin). However, the 7alpha-methyl group does not block aromatization by CYP19A1; MENT is aromatized to 7alpha-methylestradiol (7alpha-MeE2). 7alpha-MeE2 binds the estrogen receptor with potency comparable to estradiol-17beta but is structurally differentiated enough that the binding mode to CYP19A1 from the inhibitor side differs subtly, reducing the inhibitory efficacy of standard AIs (anastrozole, exemestane, letrozole), which were optimized to suppress estradiol. MENT does not bind SHBG, so essentially the entire circulating pool is free and bioavailable. At the gonadotropin axis, MENT suppresses GnRH-driven LH and FSH secretion with approximately 12x the per-mg potency of testosterone — the pharmacological basis for its contraceptive investigation. The acetate ester is hydrolyzed rapidly after injection, delivering free MENT with an effective half-life of approximately 24 hours.
Evidence Index
Quantitative claims trace to these source studies. Population, dose, and study type matter — claims from HIV-lipodystrophy trials don't transfer cleanly to healthy adults; data from supraphysiologic doses doesn't apply at TRT.
Walton 2007 documented about 90% LH and FSH suppression within 4 weeks during 48 weeks of MENT acetate implants.
The contraceptive implant dose is far below common bodybuilding injectable acetate dosing, so this is strong evidence for suppression sensitivity but not a direct hypertrophy-cycle safety estimate.
Walton 2007 documented roughly 14% HDL reduction, roughly 13% triglyceride increase, and transient systolic blood pressure elevation that normalized post-therapy.
Community injectable doses are much higher, so the direction of lipid and blood pressure concern is relevant while the exact magnitude should not be treated as a direct prediction.
Preclinical bioassay data suggests MENT has approximately 10x the myotropic potency of testosterone.
Useful for explaining why community users perceive high potency per milligram, but animal myotropic potency should not be converted directly into human cycle dose equivalence.
MENT suppresses gonadotropin secretion with approximately 12x the per-mg potency of testosterone.
The claim is directionally consistent with MENT's development as a male contraceptive, but exact per-mg comparison depends on route, ester, exposure, and endpoint.
Community injectable acetate use commonly starts around 25-50 mg/day, with 50-75 mg/day as an advanced upper range.
This is not a clinical dosing recommendation; it scopes the article's community-cycle discussion and should be separated from contraceptive implant data.
Post-cycle fertility recovery can take 6-12 months in clinical data.
Recovery timing is a fertility-planning warning, not a guarantee; injectable performance doses, stack design, baseline fertility, and PCT choices can change the timeline.
MENT acetate has an effective half-life of roughly 24 hours, making daily injection necessary for stable levels.
The article uses this to justify daily injection logistics; exact half-life varies with route, carrier, injection site, and individual clearance.
Hematocrit did not significantly change in Walton 2007, contrasting favorably with testosterone at equivalent anabolic-dose framing.
This should not be read as permission to skip CBC at community doses; the article still recommends CBC with hematocrit because performance use is higher and often stacked.
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.